EE9400040A - Composition for ophthalmic use - Google Patents

Composition for ophthalmic use

Info

Publication number
EE9400040A
EE9400040A EE9400040A EE9400040A EE9400040A EE 9400040 A EE9400040 A EE 9400040A EE 9400040 A EE9400040 A EE 9400040A EE 9400040 A EE9400040 A EE 9400040A EE 9400040 A EE9400040 A EE 9400040A
Authority
EE
Estonia
Prior art keywords
composition
ophthalmic use
ophthalmic
Prior art date
Application number
EE9400040A
Other languages
Estonian (et)
Inventor
Urtti Arto
Järvinen Tomi
Suhonen Pekka
Lehmussaari Kari
Reunamäki Timo
Alaranta Sakari
Oksala Olli
Pohjala Esko
Hanhijärvi Hannu
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Publication of EE9400040A publication Critical patent/EE9400040A/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
EE9400040A 1993-06-24 1994-08-18 Composition for ophthalmic use EE9400040A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9302203A SE501482C2 (en) 1993-06-24 1993-06-24 Composition for topical administration of bispilocarpic acid diesters to the eye in the form of an aqueous solution

Publications (1)

Publication Number Publication Date
EE9400040A true EE9400040A (en) 1995-12-15

Family

ID=20390417

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400040A EE9400040A (en) 1993-06-24 1994-08-18 Composition for ophthalmic use

Country Status (5)

Country Link
AU (1) AU6973194A (en)
EE (1) EE9400040A (en)
LT (1) LT3525B (en)
SE (1) SE501482C2 (en)
WO (1) WO1995000144A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2192965C (en) * 1994-07-11 2007-12-04 David W. Pate Anandamide analogue compositions and method of treating intraocular hypertension using same
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
WO2023225113A1 (en) * 2022-05-18 2023-11-23 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58126810A (en) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd Ophthalmic anti-inflammatory solution and preparation thereof
TW200402B (en) * 1990-08-13 1993-02-21 Senju Pharma Co
FI98815C (en) * 1990-11-30 1997-08-25 Santen Oy Process for the preparation of new pharmacologically useful ester derivatives of bispilocarpic acid

Also Published As

Publication number Publication date
AU6973194A (en) 1995-01-17
WO1995000144A1 (en) 1995-01-05
LT3525B (en) 1995-11-27
SE501482C2 (en) 1995-02-27
LTIP1970A (en) 1995-01-31
SE9302203L (en) 1994-12-25
SE9302203D0 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
BR9402379A (en) Rubber composition
IL115479A0 (en) Composition for ophthalmic use
FI941663A (en) Tricritical point composition
DE69400062T2 (en) Photopolymerizable composition
DE69416947T2 (en) Rubber composition
DE59308042D1 (en) Ophthalmic device
BR9407123A (en) Herbicidal composition
DK0614607T3 (en) Herbicide composition
EE9400040A (en) Composition for ophthalmic use
DE69423504D1 (en) PHOTOPOLYMERIZABLE COMPOSITION
EE9400039A (en) Composition for ophthalmic use
KR950703340A (en) Anti-RMS composition
DE9400967U1 (en) glasses
DE9309509U1 (en) glasses
DE9318184U1 (en) glasses
ITMI920612A1 (en) OPHTHALMIC COMPOSITION
ITMI911049A1 (en) OPHTHALMIC COMPOSITION
BR9304388A (en) Therapeutic composition for nasal use
KR940021122U (en) Glasses
KR940027321U (en) glasses
DE9315122U1 (en) glasses
DE9312472U1 (en) glasses
LTIP1969A (en) Composition for ophthalmic use
DK40893D0 (en) MICROBICID COMPOSITION
UA27833C2 (en) WOOD-GLUE COMPOSITION